Dopaminsystem und Intertemporal Choice Aufgaben
Abstract
Abstract. The dopamine (DA) system has been implicated in the mediation of cost/benefit evaluations involved in the intertemporal choices between immediate and delayed rewards. This involvement was further investigated in two studies of normal participants that had to decide between a smaller immediate and a larger delayed reward in a series of 27 decisions.In study 1 the dopamine D2/D3 receptor agonist pramipexole or placebo were administered in a double-blind cross-over protocol prior to the decisions. In study 2 the same experiment was conducted in two groups of normal participants that were homozygous for either the 7repeat or the 4 repeat variant of the exon III polymorphism of the Dopamine D4 receptor gene. Dopaminergic involvement is highlighted by the results.
Zusammenfassung. Das Dopamin (DA) System ist mit Kosten / Nutzen Abschätzungen zum Beispiel bei so genannten “Intertemporal Choice” Aufgaben in Verbindung gebracht worden. Hierbei handelt es sich um Aufgaben, bei denen zwischen einem (kleineren) sofort verfügbaren und einem später verfügbaren (größeren) Gewinn unterschieden werden muss. Es kommt zu einer Abwertung von später verfügbaren Gewinnen, wobei die Abwertungskurve einer hyperbolen Funktion folgt. Wir haben die Rolle des Dopamins in zwei weiteren Untersuchungen näher charakterisiert, die jeweils 27 Entscheidungen zwischen einem frühen und einem späteren Gewinn beinhalteten. Das Paradigma erlaubte die Schätzung der Steilheit der Abwertungskurve und teilte die Einzelentscheidungen darüber hinaus nach der Höhe des Gewinns in „niedrige“, „mittlere“ und „hohe“ Gewinne ein. In Studie 1 wurde die Abwertung unter Plazebo mit dem Dopaminagonist Pramipexol verglichen (doppel-blindes Cross-Over Design). In der Plazebobedingung wurde ein typischer Effekt der Belohnungsgröße mit weniger steiler Abwertung von großen Gewinnen gesehen. Dies war unter Pramipexol nicht der Fall, Probanden waren also weniger konservativ.
In Studie 2 untersuchten wir zwei Gruppen normaler Probanden die sich bezüglich der von ihnen getragenen Variante des Dopamin-D4-Rezeptors unterschieden (homozygot für die 7-Repeat oder 4-Repeat Variante des Exon III Polymorphismus). Träger der 7-Repeat Variante werteten Gewinne steiler ab als Träger der 4-Repeat-Variante. Erstere ist mit Impulsivität in Zusammenhang gebracht worden.
Literature
2006) Reward encoding in the monkey anterior cingulate cortex. Cerebral Cortex, 16, 1040–1055.
(1995). Modulation of intracellular cyclic AMP levels by different human dopamine D4 receptor variants. Journal of Neurochemistry, 65, 1147–1165.
(1996). Population and familial association between the D4 dopamine receptor gene and measures of Novelty Seeking. Nature Genetics, 12, 81–84.
(1989). Discount rates inferred from decisions: An experimental study. Management Science, 35, 270–284.
(2007). Immediate reward bias in humans: fronto-parietal networks and a role for the catechol-O-methyltransferase 158(Val/Val) genotype. Journal of Neuroscience, 27, 14383–14391.
(1995). A new DNA sequence assembly program. Nucleic Acids Research, 23, 4992–4999.
(2000). The effects of d-amphetamine, chlordiazepoxide, α-flupenthixol and behavioural manipulations on choice of signalled and unsignalled delayed reinforcement in rats. Psychopharmacology, 152, 362–375.
(1996). A study of the dopamine D2 receptor gene in pathological gambling. Pharmacogenetics, 6, 223–234.
(2008). Analysis of DRD4 and DAT polymorphisms and behavioral inhibition in healthy adults: implications for impulsivity. American Journal of Medical Genetics B Neuropsychiatric Genetics, 147B, 27–32.
(2003). L-Dopa medication remediates cognitive inflexibility, but increases impulsivity in patients with Parkinson’s disease. Neuropsychologia, 41, 1431–1441.
(1997). Studies of the potential role of the dopamine D1 receptor gene in addictive behaviors. Molecular Psychiatry, 2, 44–56.
(2001). The additive effect of neurotransmitter genes in pathological gambling. Clinical Genetics, 60, 107–116.
(2000). Tracking the hemodynamic responses to reward and punishment in the striatum. Journal of Neurophysiology, 84, 3072–3077.
(2005). Differential involvement of serotonin and dopamine systems in cost-benefit decisions about delay or effort. Psychopharmacology, 179, 587–596.
(2005) Differential effects of DRD4 and DAT1 genotype on fronto-striatal gray matter volumes in a sample of subjects with attention deficit hyperactivity disorder, their unaffected siblings, and controls. Molecular Psychiatry, 10, 678–685.
(2005). Neural systems of reinforcement for drug addiction: from actions to habits to compulsion. Nature Neuroscience, 8, 1481–1489.
(2001), Meta-analysis of the association between the 7-repeat allele of the dopamine D(4) receptor gene and attention deficit hyperactivity disorder. American Journal of Psychiatry, 158, 1052–1057.
(2008). Dopaminergic and glutamatergic regulation of effort- and delay-based decision making. Neuropsychopharmacology, 33, 1966–1979.
(2002). Assessing the molecular genetics of attention networks. BMC Neuroscience, 3, 14.
(2007). Hold your horses: Impulsivity, deep brain stimulation, and medication in Parkinsonism. Science, 318, 1309–1312.
(2003). Time discounting and time preference: A critical review. In: Loewenstein, G., Read, D. & Baumeister, R. (eds.) Sage, New York, NY, pp 13–86.
(2007). Pathological gambling in Parkinson’s disease: Risk factors and differences from dopamine dysregulation. An analysis of published case series. Movement Disorders, 22, 1757–1763.
(1994). Temporal discounting and preference reversals in choice between delayed outcomes. Psychonomic Bulletin and Review, 1, 383–389.
(1994). Discounting of Delayed Rewards: A Life-Span Comparison. Psychological Science, 5, 33–36.
(2007). The neural correlates of subjective value during intertemporal choice. Nature Neuroscience, 10, 1625–1633.
(2005). Single units in the pigeon brain integrate reward amount and time-to-reward in an impulsive choice task. Current Biology, 15, 594–602.
(1997). Bidding on the future: Evidence against normative discounting of delayed rewards. Journal of Experimental Psychology-General, 126, 54–70.
(1995). Modeling Myopic Decisions: Evidence for Hyperbolic Delay-Discounting within Subjects and Amounts. Organizational Behavior and Human Decision Processes, 64, 22–30.
(1996). Delay-discounting probabilistic rewards: Rates decrease as amounts increase. Psychonomic Bulletin & Review, 3, 100–104.
(1999). Heroin addicts have higher discount rates for delayed rewards than non-drug-using controls. Journal of Experimental Psychology-General, 128, 78–87.
(2005). Distributed neural representation of expected value. Journal of Neuroscience, 25, 4806–4812.
(2007). The impact of catechol-O-methyltransferase and dopamine D4 receptor genotypes on neurophysiological markers of performance monitoring. Journal of Neuroscience, 27, 14190–14198.
(1997). Golden eggs and hyperbolic discounting. Quarterly Journal of Economics, 112, 443–477.
(2006). Meta-analysis shows significant association between dopamine system genes and attention deficit hyperactivity disorder (ADHD). Human Molecular Genetics, 15, 2276–2284.
(1993). A hypervariable segment in the human dopamine receptor D4 (DRD4) gene. Human Molecular Genetics, 2, 767–773.
(2002). Dopamine system genes and attention deficit hyperactivity disorder: a meta-analysis. Psychiatric Genetics, 12, 207–215.
(1984). Tests of an equivalence rule for fixed and variable reinforcer delays. Journal of Experimental Psychology Animal Behavior Processes, 10, 426–436.
(2007). Time discounting for primary rewards. Journal of Neuroscience, 27, 5796–5804.
(2004). Separate neural systems value immediate and delayed monetary rewards. Science, 306, 503–507.
(1999). A genetic polymorphism in the promoter region of DRD4 associated with expression and schizophrenia. Biochemistry and Biophysical Research Communications, 258, 292–295.
(1999). Dopamine D4 receptor gene: novelty or nonsense? Neuropsychopharmacology, 21, 3–16.
(1997). Genetic association study between pathological gambling and a functional DNA polymorphism at the D4 receptor gene. Pharmacogenetics, 7, 345–348.
(2007). Pathological gambling associated with dopamine agonist use in restless legs syndrome. Parkinsonism and Related Disorders, 13, 535–536.
(1993). The effect of temporal constraints on the value of money and other commodities. Journal of Behavioral Decision Making, 6, 77–94.
(2008). Dopamine agonist increases risk taking but blunts reward-related brain activity. PLoS ONE, 3, e2479.
(2007). The Evolutionary Origins of Human Patience: Temporal Preferences in Chimpanzees, Bonobos, and Human Adults. Current Biology, 17, 1663–1668.
(2001). Nucleus accumbens dopamine depletions make animals highly sensitive to high fixed ratio requirements but do not impair primary food reinforcement. Neuroscience, 105, 863–870.
(2002). DRD4 and novelty seeking: Results of meta-analyses. American Journal of Medical Genetics, 114, 643–648.
(2004). Dopamine D4 receptor exon III genotype influence on the auditory evoked novelty P3. Neuroreport, 15, 2411–2415.
(1981). Some empirical evidence on dynamic inconsistency. Economics Letters, 8, 201–207.
(2006). Critical Involvement of Dopaminergic Neurotransmission in Impulsive Decision Making. Biological Psychiatry, 60, 66–73.
(1992). Multiple dopamine D4 receptor variants in the human population. Nature, 358, 149–152.
(2003). The dopamine D4 receptors and mechanisms of antipsychotic atypicality. Progress in Neuropsychopharmacology and Biological Psychiatry, 27, 1091–1099.–
(2011). Pramipexole modulates the neural network of reward anticipation. Human Brain Mapping, 32, 800–811.
(